Abstract: Objective The neoadjuvant immunotherapy of immune combined chemotherapy can coordinate and kill tumor cells. However, the immune imbalance in the process of immune activation can lead to immune-related adverse events (IRAEs). It has obvious clinical significance to explore how to develop an effective treatment plan for IRAEs through case analysis. Methods 2 cases bladder cancer patients who received neoadjuvant therapy of teriprizumab, gemcitabine and carbamazepine (GC regimen).  Result 2 patients got remission after trtatment, but got immune-related bladder inflammation. After treatment of steroids, patients immune-related bladder inflammation symptoms had improved. Robot-assisted laparoscopy laparoscopic radical cystectomy and ileal bladder replacement was performed. 2 patients were followed up, their prognosis were good. 

Key words: bladder cancer, Tereprizumab, chemotherapy, immune-related adverse events, immune-related cystitis